



Investor Relations  
Phone: (301) 897-2564  
Email: [info@spherix.com](mailto:info@spherix.com)

## SPHERIX TO PRESENT AT 2010 BIO INTERNATIONAL CONVENTION IN CHICAGO

**Bethesda, MD, May 3, 2010** - Spherix Incorporated (NASDAQ CM: [SPEX](#)), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its President, Dr. Robert Lodder, will be presenting at the 2010 BIO International Convention, which is being held at McCormick Place in Chicago, IL.

Dr. Lodder will deliver the Company's corporate presentation at the 2010 BIO Business Forum on Thursday, May 6, at 2:15 p.m. in Room 3. In addition, Spherix is participating in the pharma partnering forum and is hosting its own exhibition booth, number 2364. Ms. Leisa Dennehy, BioPharma Consultants, who was recently contracted to spearhead the Company's anti-diabetes commercial development efforts, will be attending the convention with Dr. Lodder and will be leading the business development activities for Spherix.

Early in 2010, Spherix announced completion of enrollment in its global clinical trial of D-tagatose as a novel treatment for diabetes. Spherix plans to lock the clinical trial database for the Phase 3 study this summer, and announce the efficacy results as soon as the data have been analyzed. The Company is actively seeking to sell or license the drug, or alternatively, to collaborate with another company for further development.

Held annually, the BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities. The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world's largest biotechnology exhibition.

### About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries—Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of D-tagatose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit [www.spherix.com](http://www.spherix.com).

### Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.